Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: FOXP3 targeting antisense oligonucleotides therapeutics - AUM LifeTech

X
Drug Profile

Research programme: FOXP3 targeting antisense oligonucleotides therapeutics - AUM LifeTech

Latest Information Update: 17 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AUM LifeTech
  • Class Antineoplastics; Antisense oligonucleotides; Immunotherapies
  • Mechanism of Action Forkhead transcription factor inhibitors; Regulatory T lymphocyte inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Lung cancer

Most Recent Events

  • 17 Apr 2024 FOXP3 targeting antisense oligonucleotides program is still in preclinical development for Lung cancer in USA (Parenteral)
  • 29 Aug 2022 FOXP3 targeting antisense oligonucleotide therapeutics are available for licensing as of 29 Aug 2022. https://aumlifetech.com/alliances/
  • 17 Aug 2022 AUM LifeTech receives SBIR grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for antisense oligonucleotides development in Lung cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top